GlassScriptPhysician profile
Warren Lee Jones
NPI 1841293586
$27,009.38
in general payments reported to CMS, 2019-2025
46 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,158 · 2020: $154 · 2021: $944 · 2022: $1,078 · 2023: $1,054 · 2024: $6,197 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,760 · Grant: $8,000 · Food and Beverage: $3,318 · Travel and Lodging: $1,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,760.00 |
| Grant | $8,000.00 |
| Food and Beverage | $3,317.94 |
| Travel and Lodging | $1,598.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $9,760.00 | 2024-2025 | |
| Sanofi Pasteur INC. | $9,598.00 | 2025 | |
| Novo Nordisk INC | $1,156.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,034.30 | 2019-2025 | |
| Pfizer INC. | $730.04 | 2019-2025 | |
| Lilly USA, LLC | $560.95 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $508.74 | 2019-2025 | Otezla, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $407.24 | 2020-2025 | |
| Glaxosmithkline, LLC. | $277.52 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $271.32 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $264.42 | 2019-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $226.72 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $199.45 | 2019-2025 | Eliquis, Camzyos |
| Axsome Therapeutics, INC. | $193.68 | 2023-2025 | Auvelity |
| Amarin Pharma, INC. | $183.56 | 2019-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.